InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (81 ops.)
Explore the full record of transactions filed by Carlyle Group Inc., Board Member. Insider active across 4 companies, notably ZoomInfo Technologies Inc.. Aggregated, 92 filings have been published. Total volume traded: €1.3bn. The latest transaction was disclosed on 20 April 2022 — Cession. Regulator: SEC (Form 4). The full history is free.
Declarations92 total
118,106,000 shares
Ordinary Shares, $0.00001 par value
SEC:0000899243-22-020179:0·
€5,254100 shares@ €52.53520.0005% mcap0.0% of flow
Class A Common Stock
SEC:0000899243-22-015492:0·
€4m85,323 shares@ €52.42620.39% mcap0.8% of flow
Class A Common Stock
SEC:0000899243-22-014884:0·
€450,1228,546 shares@ €52.67050.040% mcap0.1% of flow
Class A Common Stock
SEC:0000899243-22-014445:0·
€2m33,096 shares@ €53.00360.15% mcap0.3% of flow
Class A Common Stock
SEC:0000899243-22-014268:0·
€4m68,040 shares@ €54.05690.32% mcap0.7% of flow
Class A Common Stock
SEC:0000899243-22-013826:0·
€914,02717,634 shares@ €51.83320.080% mcap0.2% of flow
Class A Common Stock
SEC:0000899243-22-013116:0·
€2m29,278 shares@ €52.11170.13% mcap0.3% of flow
Class A Common Stock
SEC:0000899243-22-012792:0·
€2m28,726 shares@ €52.32760.13% mcap0.3% of flow
Class A Common Stock
SEC:0000899243-22-012506:0·
€5m100,571 shares@ €52.5070.46% mcap1.0% of flow
Class A Common Stock
SEC:0000899243-22-012091:0·
€654,10212,596 shares@ €51.92940.057% mcap0.1% of flow
Class A Common Stock
SEC:0000899243-22-011805:0·
€5,196100 shares@ €51.96290.0005% mcap0.0% of flow
Class A Common Stock
SEC:0000899243-22-011602:0·
€1m22,580 shares@ €50.42210.10% mcap0.2% of flow
Class A Common Stock
SEC:0000899243-22-006643:0·
€5m108,377 shares@ €50.2340.48% mcap1.0% of flow
Class A Common Stock
SEC:0000899243-22-006146:0·
€711,53214,064 shares@ €50.59250.063% mcap0.3% of flow
Class A Common Stock
SEC:0000899243-22-002001·
€711,53214,064 shares@ €50.59250.063% mcap0.1% of flow
Class A Common Stock
SEC:0000899243-22-002001:0·
€822,57616,241 shares@ €50.64810.072% mcap0.3% of flow
Class A Common Stock
SEC:0000899243-22-001367·
€822,57616,241 shares@ €50.64810.072% mcap0.2% of flow
Class A Common Stock
SEC:0000899243-22-001367:0·
€2bn55,722,733 shares@ €42.123100.0% of flow
Common Stock
SEC:0000899243-21-047571·
€2bn55,722,733 shares@ €42.123100.0% of flow
Common Stock
SEC:0000899243-21-047571:0·
€11m212,787 shares@ €50.60250.95% mcap4.2% of flow
Class A Common Stock
SEC:0000899243-21-047116·
€11m212,787 shares@ €50.60250.95% mcap2.0% of flow
Class A Common Stock
SEC:0000899243-21-047116:0·
€5m98,714 shares@ €52.1850.45% mcap2.0% of flow
Class A Common Stock
SEC:0000899243-21-046827·
€5m98,714 shares@ €52.1850.45% mcap1.0% of flow
Class A Common Stock
SEC:0000899243-21-046827:0·
€20m314,969 shares@ €61.99631.72% mcap7.6% of flow
Class A Common Stock
SEC:0000899243-21-046440·
25 of 92 declarations
About Carlyle Group Inc.
Carlyle Group Inc. is a leading U.S.-based private equity and alternative asset management firm, publicly traded on NASDAQ under the ticker CG. From an international corporate governance perspective, Carlyle is best understood as an active owner: a firm that does more than provide capital, but also helps shape strategy, board composition, operating discipline, and long-term value creation across portfolio companies. Its known affiliations include ZoomInfo Technologies Inc., Ortho Clinical Diagnostics Holdings plc, and PPD, Inc., which reflect Carlyle’s reach across technology-enabled business services and healthcare. ([ir.carlyle.com](https://ir.carlyle.com/static-files/bac3aa8b-b600-439e-8e33-623308ef6699?utm_source=openai)) Carlyle’s path has been defined by complex acquisitions and hands-on portfolio stewardship. In healthcare, the firm’s involvement with Ortho Clinical Diagnostics and PPD shows a recurring focus on businesses with recurring demand, technical differentiation, and significant operational upside. Carlyle’s own leadership materials emphasize its work across investments such as QuidelOrtho (formerly Ortho Clinical Diagnostics), PPD, and other healthcare assets, underscoring a long-standing sector specialization. The firm’s public communications also highlight a model built on partnering with experienced management teams, improving efficiency, and supporting innovation and geographic expansion where appropriate. ([carlyle.com](https://www.carlyle.com/ja/node/24806?utm_source=openai)) In governance terms, Carlyle is associated with decisions that are typical of a sophisticated sponsor: acquiring strategic assets, supporting leadership transitions, reinforcing board oversight, and pursuing operational improvements rather than purely financial engineering. Its work in both public and private markets gives it a broad governance footprint, and its reputation has been built on disciplined capital deployment and active engagement with management. For SEO purposes, Carlyle Group Inc. can be described as an influential governance investor with notable expertise in healthcare, technology-enabled services, and value creation through strategic board-level oversight. ([carlyle.com](https://www.carlyle.com/ja/node/25076?utm_source=openai))
